Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
Cardio Diagnostics announces that its Epi+Gen CHD heart attack risk assessment test is now available at the Family Medicine Specialists' (FMS) retail clinical location within the Meijer Supercenter in McHenry, Illinois. Meijer, a retailer with over 500 locations, primarily serves middle-aged and older adults in the Midwest, a demographic with high heart disease risk. The Epi+Gen CHD test predicts the likelihood of a heart attack or sudden death from coronary heart disease within the next three years. This initiative aligns with Meijer's commitment to health and wellness, providing accessible cardiovascular care. The partnership between Cardio Diagnostics, FMS, and Meijer aims to offer timely and accurate heart health assessments, especially in rural and suburban regions with healthcare access.
- Epi+Gen CHD test availability at Meijer Supercenter expands access to heart attack risk assessment.
- Partnership with FMS enhances healthcare services in rural and suburban Midwest areas.
- Meijer’s focus on health and wellness supports cardiovascular care for middle-aged and older adults.
- Potential dependency on retail locations for healthcare could highlight gaps in traditional healthcare systems.
Insights
Offering the Epi+Gen CHD heart attack risk assessment test at Meijer Supercenter represents a notable shift toward accessible healthcare solutions. This test assesses the probability of an individual experiencing a heart attack or sudden death related to coronary heart disease within the next three years. For a retail setting, this can significantly impact public health, particularly in suburban and rural areas where healthcare access is limited.
The integration into Meijer stores provides immediate, walk-in testing, making it easier for at-risk individuals to get timely assessments. This convenience is crucial, given the prevalence of heart disease among Gen X and Boomers, the main customer demographic at Meijer. The initiative showcases a practical application of precision cardiovascular medicine, merging retail accessibility with advanced diagnostics.
However, the success of this initiative hinges on the widespread acceptance and awareness among consumers. Education on the importance and reliability of the test will be key in driving adoption. Retail health services are expanding and this move places Cardio Diagnostics and Meijer at the forefront of this trend, potentially setting a precedent for other retailers and diagnostic firms.
The partnership between Cardio Diagnostics and Meijer Supercenter is strategically promising from a financial perspective. Featuring the Epi+Gen CHD test in Meijer locations, particularly in the Midwest where healthcare access is often challenging, aligns with market needs and demographics. This could boost Cardio Diagnostics' revenue streams by tapping into a customer base that is statistically more prone to cardiovascular issues.
From a retail perspective, this partnership enhances Meijer's healthcare offerings, potentially driving higher foot traffic and customer loyalty. The revenue implications are twofold: direct sales from the test itself and ancillary revenue from increased in-store purchases while waiting for or after consultations.
In the long term, if successful, this model could be replicated across other regions, expanding the market reach for both companies. However, it's important to monitor the initial uptake and consumer feedback to understand the true financial impact. The seamless integration and execution at the Meijer locations will be important to realizing the anticipated financial benefits.
The decision to introduce the Epi+Gen CHD test in Meijer Supercenter reflects a growing trend in healthcare retail partnerships, addressing the increasing consumer demand for convenient, on-the-spot medical services. This approach resonates well with the demographic profile of Meijer's shoppers, predominantly middle-aged and older adults who are more likely to require cardiovascular assessments.
This initiative could drive significant consumer interest by providing a tangible health benefit directly within a retail environment. It leverages the trust and convenience associated with Meijer, potentially positioning the retailer as a community health advocate. For Cardio Diagnostics, this collaboration opens up a new distribution channel, enhancing brand visibility and fostering consumer trust in their diagnostic solutions.
Nevertheless, the success of this initiative will depend on how effectively both companies can educate and encourage their customer base to utilize these services. Marketing strategies that emphasize the importance of regular heart disease screening and the convenience of in-store testing will be crucial. If executed well, this model could set a new standard in preventive healthcare, offering a lucrative and impactful service model for other retailers and diagnostic providers to emulate.
Expanding Access in the Midwest
Meijer, a privately owned and family-operated retailer based in
According to the American Heart Association, heart disease is the leading cause of death among men and women, including those aged 45 and older, making cardiovascular health a significant concern for Meijer's customer base. Meijer's commitment to health and wellness is evident through its in-store clinics and pharmacy services, which provide essential cardiovascular screenings, medication management, and personalized nutrition coaching.
"As a patient-centric company, Family Medicine Specialist is dedicated to supporting the health and wellness of families throughout
Heart Attack Prevention Tests in Retail Settings
FMS is a leading primary care and risk-bearing provider in
Employees and customers in the
These services are particularly vital in the rural and suburban regions where most Meijer locations are situated, as these areas often have limited access to healthcare facilities. Meijer’s onsite clinic partners like FMS make precision cardiovascular tests available directly where they are needed. Partnerships between retail, provider and diagnostic companies can play a critical role in improving public health outcomes in the communities they serve.
Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics stated that, “This initiative exemplifies the potential of combining retail convenience with cutting-edge medical diagnostics to deliver personalized healthcare solutions. By making Epi+Gen CHD test now available at another convenient retail location, we are working to ensure individuals can receive timely and accurate assessments of their heart attack risk, empowering them to take proactive steps towards managing their cardiovascular health. This model of accessible, community-based healthcare is a testament to the evolving landscape of preventive medicine and the importance of making advanced medical technologies widely available.”
With this latest expansion to Meijer, FMS now offers Cardio Diagnostics’ solutions across six locations, including two in a retail healthcare setting.
About Cardio Diagnostics
Cardio Diagnostics is a pioneering company in AI-powered precision cardiovascular medicine, committed to making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company leverages a proprietary AI-driven Integrated Genetic-Epigenetic Engine ("Core Technology") to develop and commercialize clinical tests aimed at improving the prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended December 31, 2023, and Form 10-Q for the period ended March 31, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627752895/en/
Investors:
Investor Relations
855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations:
Khullani Abdullahi
855-226-9991
pr@cardiodiagnosticsinc.com
Source: Cardio Diagnostics Holdings, Inc.
FAQ
What is the Epi+Gen CHD test available at Meijer Supercenter?
Where can I find the Epi+Gen CHD heart attack risk assessment test?
What is the significance of the Epi+Gen CHD test being available at Meijer?
How does the Epi+Gen CHD test benefit Meijer customers?
Why is the Epi+Gen CHD test important for rural and suburban areas?
